The shares of global leader in allogeneic cellular medicines for inflammatory diseases, Mesoblast Limited (NASDAQ: MESO) are rising on the charts today, up 10.80% to $8.00 at last check-in premarket trades. Mesoblast stock closed Thursday session at $7.22, falling -1.37%. The volume for MESO stock was 0.48 million, compared to 281.32K daily average. For positive results of its lead candidate for COVID-19, MESO stock has been rising.
The study found what?
Mesoblast has been designing allogeneic (off-the-shelf) cellular medicines for almost a decade to treat severe and life-threatening inflammatory conditions. Using the MESO proprietary mesenchymal lineage cell therapy platform, the company created a pipeline of late-stage product candidates that deliver significant reduction in the damaging inflammatory process by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Yesterday, Mesoblast announced that the 60-day results from a randomized controlled trial that included 222 ventilator-dependent COVID-19 patients with moderate to severe ARDS had been published. This trial was halted at the third interim analysis, as previously reported.
- In the pre-specified age group below 65, MESO’s Remestemcel-L reduced mortality by 46% through day 60, but not in those 65 or older.
- In patients under the age of 65, Remestemcel-L has been shown to reduce mortality by 75% and increase days alive when combined with dexamethasone, in comparison with patients on the same dose of dexamethasone.
- A total of 222 patients mechanically ventilated with severe or moderate ARDS across the US participated in the MESO trial.
- Of that group, 217 people were randomized 1:1 to either standard medical care alone or standard medical care plus two intravenous infusions of remestemcel-L at a dose 2 million cells/kg, administered within three days of each other.
During the earlier compassionate use program by Mesoblast (MESO), the same remestemcel-L dosing regimen was used on 11 of 12 patients, all younger than 65 and MESO found 75% of them achieved successful ventilation relief.